Blood pressure elevation induced by lixisenatide
10.3760/cma.j.cn114015-20210514-00563
- VernacularTitle:利司那肽致血压升高
- Author:
Chenyu ZHANG
1
;
Lin GUO
1
;
Yilei LI
1
;
Ping ZHENG
1
;
Shiting LIU
1
Author Information
1. 南方医科大学南方医院药剂科，广州 510515
- Publication Type:Journal Article
- Keywords:
Glucagon-like peptide-1 receptor;
Hypoglycemic agents;
Hypertension;
Lixisenatide
- From:
Adverse Drug Reactions Journal
2022;24(2):108-110
- CountryChina
- Language:Chinese
-
Abstract:
A 57-year-old male patient with type 2 diabetes mellitus and hypertension was changed to metformin 0.5 g orally thrice daily, acarbose 0.1 g orally thrice daily, and subcutaneous injection of lixisenatide 20 μg once daily due to poor control of blood glucose with sitagliptin, glimepiride, and metformin. The drugs used at the same time included mecobalamin injection, alprostadil injection, irbesartan, and bisoprolol. The blood pressure before treatment was 116/71 mmHg. Two hours after the first injection of lixisenatide, the patient′s blood pressure rose to 179/98 mmHg, accompanied by facial flushing and mild nausea. The blood pressure decreased to 125/74 mmHg after oral administration of 10 mg nitrendipine. Next day, the patient received subcutaneous injection of lixisenatide 10 μg, facial flushing recurred and blood pressure rose to 160/90 mmHg, which returned to normal after treatment with oral 10 mg nitrendipine. Thereafter, lixisenatide was discontinued and blood pressure elevation did not recur.
